Insmed Inc Expects $1 Billion Brinsupri Revenue

By Chris Stiles • Thursday, February 19 15:47 • Permanent Link

Insmed Incorporated has reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. The company expects full-year 2026 Brinsupri (Brensocatib) revenues to be at least $1 billion and has reiterated full-year 2026 Arikayce (Amikacin Liposome Inhalation Suspension) revenue guidance of $450 million to $470 million.

For the full-year 2025, the company reported total revenues of $606.4 million, with Brinsupri total revenues of $172.7 million and Arikayce total revenues of $433.8 million, reflecting a 19% annual growth and exceeding the upper end of the full-year 2025 guidance.

In terms of financial performance, the company reported that the cost of product revenues (excluding amortization of intangibles) was $122.9 million for the full year of 2025, compared to $85.7 million for full year 2024, primarily reflecting the increase in total product revenues for Arikayce and Brinsupri.

Research and development (R&D) expenses were $771.1 million for the full year of 2025 compared to $598.4 million for full year 2024. Selling, general, and administrative (SG&A) expenses were $701.2 million for the full year of 2025 compared to $461.1 million for full year 2024.

For the fourth quarter of 2025, Insmed reported a net loss of $328.5 million, or $1.54 per share, compared to a net loss of $235.5 million, or $1.32 per share, for the fourth quarter of 2024. For the full year of 2025, the company reported a net loss of $1,276.8 million, or $6.42 per share, compared to a net loss of $913.8 million, or $5.57 per share, for full year 2024.

As of December 31, 2025, Insmed had cash, cash equivalents, and marketable securities totaling approximately $1.4 billion. The company anticipates submitting an average of one to two Investigational New Drug (IND) applications per year from its pre-clinical research programs.

Insmed continues to anticipate that the totality of its pre-clinical research programs will comprise less than 20% of overall expenditures. The company plans to continue to invest in key activities in 2026, including commercialization and expansion of Brinsupri and Arikayce, preparation of regulatory submissions for full approval for Arikayce in the U.S., and advancement of clinical development programs for various therapies. Today the company's shares have moved 1.35% to a price of $161.42. For the full picture, make sure to review INSMED Inc's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.